相关实验视频

Updated: May 15, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

巴里西提尼布在患有严重SARS-CoV-2感染的儿童中使用的安全数据

Elspeth Bittle^1,2, Sandra Arnold², Diego R Hijano^1,2

¹Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee.

Hospital pediatrics

|April 9, 2025

概括

巴里西提尼布对患有严重COVID-19的住院儿童是安全的. 大多数早期停药是由于提供者谨慎,而不是严重的不良事件,这表明儿科患者的安全性概况有利.

科学领域:

儿科重症监护医药儿科重症监护医药
传染病传染病传染病
药理学药理学是指药理学的学科.

背景情况:

美国食品和药物管理局批准了巴里西提尼布 (一种简氏激酶抑制剂) 用于住院儿童和成人的严重COVID-19患者.
在严重的COVID-19病例中,巴里西提尼布的儿科使用存在有限的安全数据.

研究的目的:

评估巴里西提尼布在患有严重COVID-19的儿科患者的安全性和临床结果.
为了确定这一群体中巴里西提尼布早期停止治疗的不良事件和原因.

主要方法:

在2021年至2022年期间,对37名21岁以下的患者进行了回顾性病例系列,这些患者因严重的COVID-19而接受了巴里西提尼布治疗.
收集的数据包括患者特征,治疗方法,不良事件,停药原因和住院结果.

主要成果:

巴里西提尼布 (baricitinib) 治疗时间中位数为6天,大多数患者接受的是雷梅西维尔和皮质类固醇.
副作用包括肝酶升高和血栓细胞形成,所有这些都消失了. 一名患者患有深静脉血栓症.
没有死亡发生. 住院时间中位数为7天,有两名患者在补充氧气下出院.

结论:

巴里西提尼布在患有严重COVID-19的住院儿童中显示出有利的安全概况.
早期停止巴里西提尼布治疗往往是由于实验室异常,归因于提供者谨慎,而不是严重的不良事件.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

相关概念视频

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...